Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Express Scripts
McKesson
Colorcon
Harvard Business School

Last Updated: August 19, 2022

Investigational Drug Information for Merestinib


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Merestinib?

Merestinib is an investigational drug.

There have been 8 clinical trials for Merestinib. The most recent clinical trial was a Phase 1 trial, which was initiated on May 19th 2016.

The most common disease conditions in clinical trials are Neoplasm Metastasis, Neoplasms, and Lymphoma, Non-Hodgkin. The leading clinical trial sponsors are Eli Lilly and Company, Dana-Farber Cancer Institute, and Jacqueline Garcia, MD.

There are eighteen US patents protecting this investigational drug and two hundred and ninety international patents.

Recent Clinical Trials for Merestinib
TitleSponsorPhase
Merestinib on Bone Metastases in Subjects With Breast CancerEli Lilly and CompanyPhase 1
Merestinib on Bone Metastases in Subjects With Breast CancerUniversity of UtahPhase 1
Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaEli Lilly and CompanyPhase 1

See all Merestinib clinical trials

Clinical Trial Summary for Merestinib

Top disease conditions for Merestinib
Top clinical trial sponsors for Merestinib

See all Merestinib clinical trials

US Patents for Merestinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Merestinib See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
Merestinib See Plans and Pricing Methods of treating a neuroendocrine tumor SCRIPPS HEALTH (San Diego, CA) See Plans and Pricing
Merestinib See Plans and Pricing Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) See Plans and Pricing
Merestinib See Plans and Pricing Tank-binding kinase inhibitor compounds Gilead Sciences, Inc. (Foster City, CA) See Plans and Pricing
Merestinib See Plans and Pricing Compartmented pharmaceutical dosage forms Triastek, Inc. (Nanjing, CN) See Plans and Pricing
Merestinib See Plans and Pricing Targeted therapeutics MADRIGAL PHARMACEUTICALS, INC. (West Conshohocken, PA) See Plans and Pricing
Merestinib See Plans and Pricing Polymorphic compounds and uses thereof Aldeyra Therapeutics, Inc. (Lexington, MA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Merestinib

Drugname Country Document Number Estimated Expiration Related US Patent
Merestinib Australia AU2017261372 2036-05-05 See Plans and Pricing
Merestinib Canada CA3023278 2036-05-05 See Plans and Pricing
Merestinib China CN107847398 2036-05-05 See Plans and Pricing
Merestinib European Patent Office EP3452003 2036-05-05 See Plans and Pricing
Merestinib European Patent Office EP3981392 2036-05-05 See Plans and Pricing
Merestinib Hong Kong HK1249728 2036-05-05 See Plans and Pricing
Merestinib Japan JP2019520866 2036-05-05 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Express Scripts
McKesson
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.